Alecensa (Alectinib) 150mg Capsules 224-Pack | Roche China Mainland for ALK+ NSCLC | GLT

Generic Information: Alecensa (Alectinib) — China Mainland Version

The China Mainland presentation of Alecensa — known locally as 安圣莎 (盐酸阿来替尼胶囊) — is the Roche-originator alectinib capsule in its 150 mg strength, supplied as a 224-capsule multipack (four inner boxes of 56). The marketing authorization holder printed on the Chinese pack is Roche Registration GmbH. Alectinib is the second-generation anaplastic lymphoma kinase (ALK) inhibitor that displaced crizotinib as the preferred first-line option for ALK-rearranged lung cancer, largely because of what it does inside the skull: it penetrates the blood-brain barrier far better than its predecessor.

What Is Alecensa (Alectinib) Used For?

Chinese oncologists prescribe Alecensa for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer, both as initial therapy and after crizotinib failure. Chinese treatment guidelines mirror the global position: molecular confirmation of the ALK rearrangement comes first, then alectinib as category-preferred systemic therapy. Families in China and neighboring markets frequently ask GLT about the 224-capsule presentation because a full treatment month at the standard schedule consumes exactly one multipack.

How Does Alecensa (Alectinib) Work?

Alectinib switches off the ALK fusion protein that drives uncontrolled division in ALK-rearranged tumors, and it also inhibits RET tyrosine kinase activity. Its active metabolite (M4) carries comparable potency, and because the molecule is not a substrate of the P-gp or BCRP efflux pumps that guard the blood-brain barrier, therapeutic concentrations build up in brain tissue and in the cerebrospinal fluid. That pharmacologic property is the clinical reason brain-metastasis control on alectinib is dramatically better than on first-generation ALK drugs.

Indications of Alecensa (China)

The Chinese label covers first-line treatment of ALK-positive metastatic NSCLC and use after progression on crizotinib, matching the globally harmonized label. Oncology teams in mainland China also see the label updated for adjuvant therapy following resection of ALK-positive tumors of 4 cm or larger or with nodal involvement, reflecting the practice-changing ALINA evidence. None of these indications apply without a validated ALK test result.

Dosage and Administration

The recommended schedule is 600 mg twice daily — four 150 mg capsules in the morning and four in the evening, taken with food — for a daily total of 1,200 mg, which is exactly one 224-capsule multipack every four weeks. Capsules are swallowed whole; never split, dissolve or chew them. If toxicity demands, dose steps go down to 450 mg twice daily and then 300 mg twice daily, stopping permanently if the lowest step remains intolerable. Missed doses can be made up unless the next dose is due within six hours, and vomiting is not a reason to re-dose.

Side Effects of Alecensa

Across the pivotal programme the effects seen most often were constipation, swelling of the ankles and around the eyes, muscle and joint aches, tiredness, low hemoglobin, rash and cough. The monitoring agenda matters more than the raw list: liver enzymes checked every two weeks through the first months, creatine phosphokinase on the same rhythm while muscle symptoms are queried, heart rate and blood pressure at each visit because alectinib slows cardiac conduction, and prompt imaging for any new breathlessness or cough that could signal interstitial lung disease. Photosensitivity is characteristic of this drug, so sun protection becomes a daily habit, and significant anemia — occasionally hemolytic — warrants workup.

Storage Instructions

Keep the multipack below 30°C, dry and away from direct light, in the original carton. Once an inner blister strip is opened it should be used within its labeled in-use period. No refrigeration. Store where children cannot reach, and take expired capsules to a pharmacy for disposal.

Why Choose Alecensa from GLT?

The mainland-Chinese presentation has two practical advantages GLT customers care about: authenticity is easy to confirm (Chinese labeling, Roche Registration GmbH as MAH, security print), and after national reimbursement negotiations transformed its price, the 224-capsule China pack typically lands far below US list pricing — commonly quoted at roughly 70%–80% below what the same month of therapy costs in the United States. GLT ships the original Roche multipack with batch documentation, accepts institutional tenders as well as family orders, and keeps both a pharmacist-checked supply chain and a direct line to a human being on WhatsApp +86 15234153837 and [email protected].

How to Order Alecensa (Alectinib)

Send GLT the product name and quantity, receive a formal quotation with courier options, confirm payment, and we dispatch with full paperwork for customs. Institutional buyers can request CoA and batch photographs before committing. Write to [email protected] or message WhatsApp +86 15234153837 — quotations usually go out within one working day, and recurring monthly orders can be scheduled in advance so treatment is never interrupted.

FAQ

How many capsules are in the China pack? 224 capsules of 150 mg — four inner boxes of 56 — which matches one month at the standard eight-capsules-per-day schedule.

Is the Chinese Alecensa the same medicine as the US one? Yes — same Roche-originator molecule and strength; only the packaging, language, and marketing authorization holder differ.

Does alectinib work against RET too? It inhibits RET kinase in the laboratory, but patients with RET-driven cancers are treated with dedicated RET inhibitors; alectinib's approved use is ALK-positive disease.

Can GLT supply other alectinib generics? Yes — Bangladeshi and Laotian generic versions are listed on our site; ask us for a side-by-side quotation comparing pack sizes and landed cost.

What documents ship with the order? Batch/lot details and the standard export documentation set; institutions can request CoA copies in advance.